Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study

NCT02261883 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT02261883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02261883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
Lead sponsor
United Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
July 29, 2015
Completion date
May 17, 2023
Enrollment
42 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

persistent pulmonary hypertension of the newborn